Light Sciences Oncology, Inc. Stumbles in Clinical Trial, Layoffs Loom

Light Sciences Oncology, the Bellevue, WA-based developer of an unusual drug/device combo treatment for cancer, has failed in a pivotal clinical trial and is preparing to make deep cuts, including layoffs, Xconomy has learned from sources familiar with the situation. The privately-held company has raised well over $130 million since its founding in 1995, from a big-name group of investors that includes Essex Woodlands Health Ventures, Johnson & Johnson Development Corporation, Novo A/S, Scandinavian Life Science Venture, and the late Microsoft treasurer Craig Watjen—who put more than $50 million of his own money into the company before he died a year ago from cancer. Bob Littauer, the company’s chief financial officer, declined to respond to requests for comment about the outcome of the trials or any subsequent corporate decisions.

Back to news